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Received December 14, 2010; accepted June 15, 2011AbstractBackground: Homeostasis model assessment of insulin resistance (HOMA-IR) is a surrogate estimate of directly measured insulin resistance that
been robustly proven to be associated with diabetes and cardiovascular disease. The purpose of this study was to evaluate the use of several
simple indicators to identify postmenopausal women with insulin resistance estimated by HOMA-IR.
Methods: We recruited 262 naturally postmenopausal women without overt diabetes for the study. HOMA-IR values were calculated from
fasting glucose and insulin levels. Multiple linear regression analyses were carried out to detect determinants of HOMA-IR. Insulin resistance
was conventionally defined as the upper quartile of the HOMA-IR values. The diagnostic power of clinical and biochemical markers for insulin
resistance was assessed using receiver operating characteristic curves.
Results: Some 90% of the women with HOMA-IR  2.8 (75th percentile as cutoff) showed abnormal glucose metabolism and 45% of them had
silent diabetes (odds ratio 6.09, 95% CI 3.17 e 11.73 vs. those with HOMA-IR < 2.8). Results revealed that uric acid, body mass index, waist
circumference, alanine aminotransferase, triglycerides, and high-density lipoprotein cholesterol were important determinants of HOMA-IR in
these women. Using uric acid  5.0 mg/dL as a cutoff point, we could diagnose insulin resistance with 75.4% sensitivity and 73.1% specificity.
Conclusion: Postmenopausal women with HOMA-IR-estimated insulin resistance were at high risk of glucose abnormalities in this study. High
HOMA-IR values were significantly associated with six clinical and biochemical indicators. Among these, high serum uric acid levels seemed to
be a useful marker identifying postmenopausal women with insulin resistance. This study was registered at clinicaltrials.gov as NCT00945271.
Copyright  2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Investigators in the Framingham study found that women
had a four-fold higher risk for subsequent cardiovascular
disease (CVD) in the 10 years following natural menopause.1
The transition from pre- to postmenopause is associated with
the emergence of many cardiovascular risk factors such as* Corresponding author. Dr. Chii-Min Hwu, Section of Endocrinology and
Metabolism, Department of Medicine, Taipei Veterans General Hospital, 201,
Section 2, Shi-Pai Road, Taipei 112, Taiwan, ROC.
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doi:10.1016/j.jcma.2011.08.014abdominal obesity, dyslipidemia, and insulin resistance.2
Homeostasis model assessment of insulin resistance (HOMA-
IR) is a surrogate estimate of directly measured insulin resis-
tance based on measurements of fasting plasma glucose (PG)
and insulin concentrations.3 It has been robustly proven that
HOMA-IR is associated with type 2 diabetes mellitus (DM) and
CVD.4 Lejskova´ et al recently reported that postmenopausal
women with high HOMA-IR values had a three-fold increased
risk of the metabolic syndrome compared to those with low
HOMA-IR.5 In the Bruneck study, Bonora et al found that
women with high HOMA-IR values had a 2.0- to 2.5-fold
higher risk of subsequent CVD after 15-year follow-up.6hinese Medical Association. All rights reserved.
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two-fifths of CVD events occurred in participants with HOMA-
IR levels in the upper 25% in the FraminghamOffspring Study.7
Song et al showed that HOMA-IR is particularly useful in
predicting the development of DM in individuals with fasting
PG < 126 mg/dL compared to other markers such as fasting
insulin in postmenopausal women.8 Ausk et al analyzed data for
3511 participants with fasting PG < 126 mg/dL and without
a known history of DM and found that individuals in the top
HOMA-IR quartile had significantly greater mortality than
those in the bottom quartile.9 This compelling evidence indi-
cates that individuals with HOMA-estimated insulin resistance
warrant more medical attention with regard to prevention of
DM, CVD and premature death.
Although HOMA-IR may be a potential tool for identifying
individuals at risk of adverse outcomes, its use is limited at
present because fasting levels of insulin are not measured
routinely, partly owing to the cost of measurement and a lack of
assay standardization.10 Given the apparent clinical importance
of identifying postmenopausal women with high HOMA-IR
values, an investigation of the utility of simple indicators,
including anthropometric measurements and routine biochem-
istry tests, in accomplishing this task seems worthwhile. Our
aim was to evaluate the use of several simple indicators in
identifying postmenopausal women with insulin resistance
estimated by HOMA-IR. Our results may provide clinicians
with clues for identifying postmenopausal women who are
susceptible to DM and CVD.
2. Methods2.1. ParticipantsFrom October 2009 to July 2010, 262 naturally post-
menopausal women who had not menstruated within the last
12 months were recruited from a hospital-based research
clinic. The women were volunteers for health surveys and
participants in observational studies. Those who had under-
gone hysterectomy and/or oophorectomy before or within 12
months of natural menopause were excluded. Women with
a known history of DM or fasting PG > 126 mg/dL were
excluded from the study. The participants did not have liver,
kidney, blood, heart or neurological diseases. None of them
had experienced acute illness in the previous 6 months.
Concomitant use of anti-lipid agents, glucose modification
agents, or hormone replacement was not allowed during the
study. The study protocol was approved by the institutional
review board of the hospital, and written informed consent was
obtained from all participants before they entered the study.2.2. Clinical examinationThe participants underwent anthropometric measurement at
8.00 AM after an overnight fast of 8e10 hours. Weight was
measured to the nearest 0.1 kg. Height was measured to the
nearest millimeter. Body mass index (BMI) was calculated as
weight divided by height squared (kg/m2). Waist circumference(WC) was measured at the level of the umbilicus to the nearest
millimeter after expiration using an anthropometric tape while
the participant breathed quietly.11 Blood pressure (BP) was
measured using an automated oscillometric BP recorder
(Dinamap 1864SX, Critikon, Tampa, FL, USA) after the indi-
vidual had rested quietly for 10 minutes. Fasting blood samples
were collected for measurement of PG, insulin, lipids, and other
biochemical parameters. Then 75 g of glucose monohydrate (in
300 mL of water) was administered to each participant to drink
over 5 minutes.11 Blood samples were taken 120 minutes after
glucose loading for an oral glucose tolerance test. The samples
were centrifuged as soon as possible and stored at e20 C until
assay. Participants were interviewed during the oral glucose
tolerance test regarding demographic characteristics and
medical history. If an individual was taking antihypertensive
medication or had diastolic BP > 90 mmHg or systolic
BP > 140 mmHg, she was classified as hypertensive.2.3. MeasurementsPG was measured by a glucose oxidase method using
a glucose analyzer (model 2300, YSI, Yellow Springs, OH,
USA). Plasma insulin was measured using an automated
chemiluminescence system (ADVIA Centaur Immunoassay
System, Siemens Healthcare Diagnostics, Deerfield, IL, USA).
The intra- and inter-assay coefficients of variation (CV) for
insulin measurement were 3.7% and 4.4%, respectively. Serum
lipids and biochemical parameters were measured using
commercial assay kits (Roche Diagnostics, Basel, Switzerland)
on an automatic blood chemistry analyzer (Roche-Hitachi 7180,
Roche Diagnostics, Basel, Switzerland). Serum high-density
lipoprotein cholesterol (HDL-C) was determined using a poly-
ethylene glycol-modified enzymatic cholesterol assay after
dextran sulfate precipitation. The intra-assay CVs for total
cholesterol (TC), total triglyceride (TG), and HDL-C assays
were 2.1%, 1.1%, and 1.4%, and inter-assay CVs were 3.1%,
2.6%, and 3.0%, respectively.2.4. Statistical analysisData are expressed as mean (S.D.) or n (%). The HOMA-IR
index was calculated according to the formula: HOMA-
IR ¼ fasting PG (mmol/L)  fasting insulin (mU/L)/22.5.3,4
The participants were divided into four groups according to
HOMA-IR value quartiles. Individuals with HOMA-IR  2.8
(75th percentile cutoff) were considered to be insulin-resistant
according to European Group for the Study of Insulin Resis-
tance recommendation.12 Because of their skewed distribu-
tions, fasting TG, alanine aminotransferase (ALT), and
HOMA-IR were analyzed after logarithmic transformation.
Clinical and biochemical characteristics were compared using
c2 tests and one-way analysis of variance with a post-hoc
Duncan test for categorical and continuous variables, respec-
tively. Pearson correlation procedures were used to test the
correlation of log HOMA-IR with clinical and biochemical
indicators. The relative contributions of significant correlates
to log HOMA-IR were then evaluated by multiple linear
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curves were applied to determine optimal cutoff values for
clinical and biochemical markers for the diagnosis of insulin
resistance (estimated by HOMA-IR  2.8 in this study). For
each marker tested, sensitivity and specificity were calculated
for the diagnosis of HOMA-estimated insulin resistance.13 The
area under the ROC curve (AROC) for each marker was
calculated from a plot of sensitivity versus 1  specificity.
Accuracy was determined from sensitivity and specificity,
because the true positive rate (prevalence) of HOMA-IR  2.8
was known, using the equation: accuracy ¼ (sensitivity 
prevalence) þ [specificity  (1  prevalence)]. The positive
likelihood ratio (LR) was calculated as sensitivity/
(1  specificity).13 A positive LR > 1 indicates that the
probability of a positive test for an individual with the disease is
greater than the probability of a positive test for an individual
without the disease. The negative LR was calculated as
(1  sensitivity)/specificity.13 A negative LR < 1 indicates that
the probability of a negative test for an individual with the
disease is less than the probability of a negative test for an
individual without the disease. Analyses were performed using
the SPSS program (Version 16.0, SPSS Inc., Chicago, IL, USA).
A p value < 0.05 was considered statistically significant.
3. Results
The clinical characteristics of the participants by HOMA-
IR quartiles are shown in Table 1. The four groups were
comparable in age, height, diastolic BP, total cholesterol, and
low-density lipoprotein cholesterol. There were significantTable 1
Descriptive characteristics of the study participants by HOMA-IR quartiles
HOMA
Q1 (0.48e1.18) Q2 (1.19e1.7
n 65 66
Age (y) 59.2 (4.7) 59.7 (5.1)
Weight (kg) 52.6 (7.1) 55.6 (6.8)
Height (cm) 155.8 (6.0) 156.2 (4.5)
BMI (kg/m2) 21.6 (2.4) 22.8 (2.3)
WC (cm) 76.5 (7.1) 80.9 (7.4)
Systolic BP (mmHg) 112 (20) 118 (16)
Diastolic BP (mmHg) 67 (10) 68 (9)
UA (mg/dL) 4.3 (0.8) 4.7 (0.9)
ALT (U/L) 19 (21) 20 (114)
Log ALT 1.29 (0.11) 1.33 (0.17)
Fasting PG (mg/dL) 91 (6) 95 (6)
Total cholesterol (mg/dL) 212 (43) 214 (33)
LDL-C (mg/dL) 123 (36) 127 (30)
TG (mg/dL) 60 (309) 80 (406)
Log TG 1.82 (0.19) 1.93 (0.21)
HDL-C (mg/dL) 74 (18) 68 (17)
Hypertensive (n, %) 7 (10.8%) 9 (13.6%)
Data are expressed as mean (S.D.) or n (%). The median (range) for ALT and TG v
compare differences among the four groups.
ALT ¼ alanine aminotransferase; BMI ¼ body mass index; BP ¼ blood pressure; H
assessment of insulin resistance; LDL-C, low-density lipoprotein cholesterol; log AL
of fasting TG (in mg/dL); PG ¼ plasma glucose; Q1 ¼ first quartile for HOMA-IR
triglycerides; UA ¼ uric acid; WC ¼ waist circumference.differences in weight, BMI, WC, uric acid (UA), systolic BP,
fasting PG, log ALT, log TG and HDL-C among the four
groups. Women with high HOMA-IR (in the fourth quartile,
Q4) were heavier and had higher BMI, WC, systolic BP, and
serum UA, fasting TG and ALT than those in the first quartile
(Q1) group (compared by post hoc Duncan test, all p < 0.05).
Women in the Q4 group also had significantly lower HDL-C
concentrations than women in the Q1 group ( p < 0.05).
More than 30% of the women with HOMA-IR  2.8 already
had hypertension. Some 90% of the women with HOMA-
IR  2.8 exhibited abnormal glucose metabolism: 45% had
silent DM (i.e. fasting PG < 126 and 2-h PG  200 mg/dL),
and 43% had impaired glucose tolerance (IGT, 140  2-h
PG < 200 mg/dL) (Fig. 1). The odds ratio of silent DM for
women with HOMA-IR  2.8, compared with those with
HOMA-IR < 2.8, was 6.09 (95% confidence interval,
3.17e11.73).
There were significant correlations between log HOMA-IR
and several clinical and biochemical indicators, including
BMI, WC, systolic BP, UA, log ALT, log TG and HDL-C (all
p < 0.05). Multiple linear regression results revealed that
BMI, WC, UA, log ALT, log TG, and HDL-C were important
determinants of log HOMA-IR in these women (Table 2). The
regression model explained 50.4% of the variance of log
HOMA-IR. We used ROC curve analysis to assess the diag-
nostic power of the above indicators for the diagnosis of
insulin resistance (estimated by HOMA-IR  2.8). The cutoff
values and AROC for UA, TG, ALT, BMI, WC, and HDL-C
for HOMA-IR  2.8 are listed in Table 3. Using
UA  5.0 mg/dL as a cutoff point, we could diagnose HOMA--IR quartile (range) p
3) Q3 (1.74e2.78) Q4 ( 2.8)
66 65
60.2 (5.2) 59.0 (5.1) 0.55
58.5 (6.2) 63.3 (8.6) <0.0001
155.6 (5.9) 157.0 (5.0) 0.42
24.2 (2.9) 25.7 (3.3) <0.0001
84.4 (7.6) 88.8 (9.0) <0.0001
119 (20) 124 (17) 0.008
68 (10) 71 (9) 0.14
4.7 (0.8) 5.6 (1.2) <0.0001
20 (80) 28 (105) d
1.32 (0.15) 1.46 (0.19) <0.0001
100 (7) 104 (9) <0.0001
209 (34) 216 (36) 0.69
122 (31) 134 (32) 0.14
96 (291) 118 (374) d
2.00 (0.26) 2.10 (0.18) <0.0001
64 (18) 54 (11) <0.0001
19 (28.8%) 22 (33.8%) 0.002
alues is also presented. One-way analysis of variance or a c2 test was used to
DL-C ¼ high-density lipoprotein cholesterol; HOMA-IR ¼ homeostasis model
T ¼ logarithmic transformation of ALT (in U/L); log TG ¼ log transformation
; Q2 ¼ second quartile; Q3 ¼ third quartile; Q4 ¼ fourth quartile; TG ¼ total
Fig. 1. Distribution of glucose abnormalities in the study participants. We used
the following criteria to define glucose abnormalities in the study: silent DM,
fasting PG < 126 mg/dL and 2-h PG  200 mg/dL; combined IFG and IGT,
100  fasting PG < 126 mg/dL and 140  2-h PG < 200 mg/dL; IGT only,
fasting PG < 100 mg/dL and 140  2-h PG < 200 mg/dL; IFG only,
100  fasting PG < 126 mg/dL and 2-h PG < 140 mg/dL; NGT, fasting
PG < 100 mg/dL and 2 h PG < 140 mg/dL. There were significant differences
in glucose abnormalities between women with HOMA-IR  2.8 and those
with HOMA-IR < 2.8 according to c2 tests. DM ¼ diabetes mellitus; HOMA-
IR ¼ homeostasis model assessment of insulin resistance; IFG ¼ impaired
fasting glucose; IGT ¼ impaired glucose tolerance; NGT ¼ normal glucose
tolerance; PG ¼ plasma glucose.
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specificity in these women. Furthermore, this diagnostic test
(UA  5.0 mg/dL for HOMA-IR  2.8) yielded the highest
AROC and the highest accuracy among the parameters tested
in the study (Table 3). All the markers except for HDL-C
showed small increases in association with HOMA-IR  2.8
(positive LR of 2e5) (Table 3). All the markers except for
ALT had negative LR values in the range 0.2e0.5 (Table 3).
Thus, the probability of a negative test result for an individual
with HOMA-IR  2.8 is less than the probability of a negative
test for an individual without the disease.
4. Discussion
In this cohort of postmenopausal women, we demonstrated
that approximately 45% of the women with high HOMA-IR
values had silent DM (Fig. 1). Silent DM, also known asTable 2
Results of the multiple regression analyses with log HOMA-IR as the
dependent variable (n ¼ 262)
Variable entered Estimate SE p
BMI 0.016 0.007 0.021
WC 0.006 0.002 0.009
Systolic BP 0.001 0.001 0.54
Diastolic BP 0.0001 0.002 0.78
UA 0.046 0.012 <0.0001
Log ALT 0.314 0.073 <0.0001
Log TG 0.143 0.067 0.033
HDL-C 0.003 0.001 0.004
Abbreviations as for Table 1.isolated post-challenge hyperglycemia, is a form of DM with
fasting PG < 126 mg/dL but 2-h PG  200 mg/dL.14 Long-
term studies have shown that individuals with silent DM
have equivalent CVD and total mortality risks as those with
known DM.14 Qiao et al urged health professionals to detect
silent DM in high-risk individuals for the prevention of
adverse outcomes.15 Our research provides a clue to identifi-
cation of silent DM cases among postmenopausal women. The
odds of silent DM for women with HOMA-IR  2.8 were six-
fold greater than the odds for women with HOMA-IR < 2.8. It
seems that high HOMA-IR was a good marker for silent DM
in these women. Moreover, the women with high HOMA-IR
values also had an increased cardiovascular risk profile,
including high BP and dyslipidemia (Table 1). Together, these
findings suggest that insulin resistance (estimated by high
HOMA-IR values in our study), although generally under-
recognized in clinical practice, may have important health
consequences for postmenopausal women.2,8,16
Given the apparent importance of insulin resistance as
a marker of silent DM, it would seem useful to identify
insulin-resistant individuals in clinical practice. Unfortunately,
the HOMA-IR value used in the current study to define insulin
resistance cannot be translated to other situations unless the
insulin concentrations are measured in the same laboratory.17
Reaven suggested that identification of metabolic variables
closely related to insulin resistance, and for which standard-
ized laboratory measurements are available, might be useful in
determining individuals with insulin resistance.18 With this
approach, we demonstrated that high UA levels, as well as five
other parameters, can identify postmenopausal women who
are insulin-resistant. Our data show that UA was a major
determinant of HOMA-IR (Table 2), and using UA  5.0 mg/
dL as a cutoff point, we could diagnose HOMA-estimated
insulin resistance in postmenopausal women with 75.4%
sensitivity and 73.1% specificity. Several epidemiologic
studies have demonstrated that serum UA levels are positively
associated with insulin resistance and its corresponding
hyperinsulinemia.19,20 Facchini and colleagues explained that
insulin resistance decreases urinary UA clearance, which leads
to an increase in serum UA concentrations.21 Individuals with
insulin resistance might also have impairment in the glycolytic
pathway, which would result in an increase in the flux of
glucose-6-phosphate to the hexose monophosphate shunt and
accumulation of substrates for UA production, leading to
hyperuricemia.22 However, evidence also shows that hyper-
uricemia may actually promote or worsen insulin resistance
owing to its detrimental effects on endothelial dysfunction.22
Recently, the Rancho Bernardo Study suggested that serum
UA can independently predict CVD mortality, especially in
older adults with glucose abnormalities.23 If our goal is to
identify insulin-resistant women at risk of CVD, serum UA
may offer advantages beyond the need to identify insulin
resistance.
Nilsson et al recruited 223 elderly Swedish women repre-
sentative of a general population to study the associations
between WC and insulin resistance.24 The investigators re-
ported that the optimal WC cutoff for insulin resistance
Table 3
Diagnostic power of clinical and biochemical indicators for homeostasis model assessment-estimated insulin resistance in postmenopausal women
Variable AROC Cutoff Sensitivity (%) Specificity (%) Accuracy (%) Positive LR Negative LR
UA (mg/dL) 0.777 5.0 75.4 73.1 73.7 2.80 0.34
TG (mg/dL) 0.763 100 78.5 69.5 71.8 3.28 0.31
ALT (U/L) 0.753 25 60.0 77.7 73.3 2.69 0.51
BMI (kg/m2) 0.748 23.2 78.5 64.0 67.6 2.18 0.34
WC (cm) 0.747 86 63.1 75.6 72.5 2.59 0.49
HDL-C (mg/dL) 0.260 <66 86.2 54.3 62.2 1.89 0.25
AROC ¼ area under the receiver operating characteristic curve; LR ¼ likelihood ratio; other abbreviations as for Table 1.
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with WC > 88 cm had a relative risk of 5.6 of being insulin-
resistant compared to those with WC  88 cm in their study.24
Although it has been suggested that Asians might have a lower
WC cutoff than Europeans at equivalent risk,25 surprisingly,
the WC cutoff for insulin resistance in our study was close to
that for the Nilsson study (Table 3). Bao et al used magnetic
resonance imaging to measure visceral fat area in 615 middle-
aged Chinese women and found that the optimal WC cutoff for
abdominal obesity was 85 cm.26 Considering the significant
contribution of visceral fat accumulation to the features of
insulin resistance, the current WC cutoff for Chinese women
according to the new international harmonization criteria27
may not be appropriate in term of diagnosis of insulin resis-
tance. More studies are needed to clarify this issue.
Our study has some limitations. First, the study cohort was
naturally postmenopausal women without a history of DM. The
ability of the same indicators or cutoffs to identify high HOMA-
IR conditions in other populations is unproven. Second, insulin
resistance is distributed continuously throughout the general
population, and there is no consensus on criteria to classify
individuals as being insulin-resistant or insulin-sensitive.
If alternative thresholds for high HOMA-IR values were
selected, there might be widely disparate results in the
performance of clinical markers for identifying insulin resis-
tance. Finally, because a common reference system for insulin
measurements is not finalized, the absolute HOMA-IR values
used in this study cannot be translated to other samples
measured using a different insulin assay. Of course, the use of
simple indicators to identify individuals who are insulin-
resistant is not ideal. The major virtue of this approach is
that these parameters are determined by a clinically routine
method, and the sensitivity and specificity for the diagnosis of
HOMA-estimated insulin resistance are reasonable. However,
our findings also emphasize the need for better efforts to
identify insulin-resistant individuals than the use of these
simple markers. A standardized insulin assay would help to
close the gap between epidemiological research and real-
world practice in finding cases of insulin resistance.18 Until
that day arrives, our ability to identify insulin-resistant indi-
viduals will rely heavily on the use of simple clinical markers.
In conclusion, our study demonstrated that postmenopausal
women with HOMA-estimated insulin resistance were at high
risk of silent DM. High HOMA-IR values were significantly
associated with components of the metabolic syndrome, as
well as with serum UA concentrations. High UA levels( 5.0 mg/dL) seem to be a useful indicator for identifying
postmenopausal women with insulin resistance.
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